Multinational CMV Outcomes, Treatment Patterns and Healthcare Resource Utilization Study following Hematopoietic Stem Cell Transplant (OTUS HSCT)

Takeda (United States)0 个研究点目标入组 379 人开始时间: 2021年11月25日最近更新: 2023年9月4日

试验速览

暂无简介。

•Cohort 1: Resistant/refractory/intolerant inclusion criteria:
•1. Aged =18 years at the time of the HSCT
•2. Received an HSCT after 1 January 2014
•3. Diagnosed with CMV infection any time after the HSCT date
•4. Characterized as resistant to currently available treatments, OR refractory to currently available treatments, OR considered intolerant to currently available treatments
•5. Follow-up data are available for at least 12 months (1 year) after being characterized in item (4) (above) or until death, whichever occurs first
•Cohort 2: Pre-emptive treatment for CMV viremia inclusion criteria:
•1. Aged =18 years at the time of the HSCT
•2. Received an HSCT after 1 January 2017
•3. Diagnosed with CMV viremia any time after the HSCT date
•4. Received pre-emptive treatment
•5. Follow-up data are available for at least 12 months (1 year) after being characterized in item (4) (above) or until death, whichever occurs first

发起方

Takeda (United States)